PROJECTS
EVIDENCE ACROSS MATERIALS, MECHANISMS AND PRODUCTS
A2P2 has been applied across medical-device and adjacent regulated-product environments, including sterile barrier packaging, biopharmaceutical single-use systems, implantable polymers, gamma-irradiated assemblies, adhesives, tubing and industrial membrane systems.
The purpose of every deployment is the same: identify the governing behaviour, design the right experiment, calculate a defensible time equivalence and connect the result to a decision that the organisation can explain.
Deployments are confidential by default. The summaries below are anonymised. Study designs, source data and detailed outputs are available only where disclosure is authorised or under NDA.
SELECTED OUTCOMES
BIOREACTOR STABILITY PROGRAMME
A material-specific A2P2 programme reduced an ageing pathway from 337 days to 71 days while retaining an explicit scientific basis for the acceleration conditions and verification plan.
ADHESIVE SHELF-LIFE EXTENSION
A2P2 supported an evidence-led shelf-life extension associated with approximately £40 million in avoided waste. The work focused on the governing adhesive behaviour rather than treating the full assembly as a uniform ageing system.
MEMBRANE FIELD VALIDATION
A2P2 predictions for a polyamide composite separation membrane were evaluated against eight years of continuous service in pharmaceutical-grade water operation, providing a long-duration comparison between accelerated prediction and field behaviour.
TUBING LIFE-CYCLE PROGRAMME
A combined cleaning, drying, inspection and performance-verification programme extended operational tubing life beyond the original replacement interval while maintaining defined acceptance criteria.
DISCUSS THE RELEVANT EVIDENCE
Qualified organisations can request an anonymised technical discussion under NDA.
